Zhitong Finance App News, Lingrui Pharmaceutical (600285.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for montelukast sodium chewables approved and issued by the State Drug Administration. The montelukast sodium chewable tablets were developed by MSD and launched in China in 1999, with the trade name “Shunerning”. Indications for this product are: It is suitable for prevention and long-term treatment of asthma in children aged 2 to 14, including preventing daytime and nighttime asthma symptoms, treating asthmatics sensitive to aspirin, and preventing exercise-induced bronchospasm; suitable for reducing symptoms caused by allergic rhinitis (seasonal allergic rhinitis and perennial allergic rhinitis in children aged 2 to 14).